{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:50:04Z","timestamp":1764240604852,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971859 82172118"],"award-info":[{"award-number":["81971859 82172118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In preclinical experiments, we demonstrated that the 5-HT3 receptor antagonist granisetron results in reduced inflammation and improved survival in septic mice. This randomized controlled trial was designed to assess the efficacy and safety of granisetron in patients with sepsis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Adult patients with sepsis and procalcitonin\u00a0\u2265\u00a02\u00a0ng\/ml were randomized in a 1:1 ratio to receive intravenous granisetron (3\u00a0mg every 8\u00a0h) or normal saline at the same volume and frequency for 4\u00a0days or until intensive care unit discharge. The primary outcome was 28-day all-cause mortality. Secondary outcomes included the duration of supportive therapies for organ function, changes in sequential organ failure assessment scores over 96 h, procalcitonin reduction rate over 96 h, the incidence of new organ dysfunction, and changes in laboratory variable over 96\u00a0h. Adverse events were monitored as the safety outcome.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The modified intention-to-treat analysis included 150 septic patients. The 28-day all-cause mortalities in the granisetron and placebo groups were 34.7% and 35.6%, respectively (odds ratio, 0.96; 95% CI, 0.49\u20131.89). No differences were observed in secondary outcomes. In the subgroup analysis of patients without abdominal or digestive tract infections, the 28-day mortality in the granisetron group was 10.9% lower than mortality in the placebo group. Adverse events were not statistically different between the groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Granisetron did not improve 28-day mortality in patients with sepsis. However, a further clinical trial targeted to septic patients without abdominal\/digestive tract infections perhaps is worthy of consideration.<\/jats:p>","DOI":"10.3389\/fphar.2022.1013284","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:14:04Z","timestamp":1670908444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): A single-center, single-blinded, randomized, controlled clinical trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianbin","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwei","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoyou","family":"Shichen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/J.JPHS.2021.08.005","article-title":"Granisetron attenuates liver injury and inflammation in a rat model of cecal ligation and puncture-induced sepsis","volume":"147","author":"Aboyoussef","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.COPH.2011.02.004","article-title":"5-HT and the immune system","volume":"11","author":"Ahern","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/ANNUREV.MED.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/J.CHEST.2020.02.065","article-title":"Combined treatment with hydrocortisone, vitamin C, and thiamine for sepsis and septic shock: A randomized controlled trial","volume":"158","author":"Chang","year":"2020","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/S00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1590\/S0104-11692013000300020","article-title":"Quality of life of severe sepsis survivors after hospital discharge","volume":"21","author":"Contrin","year":"2013","journal-title":"Rev. Lat. Am. Enferm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/CC12616","article-title":"Mortality and quality of life in the five years after severe sepsis","volume":"17","author":"Cuthbertson","year":"2013","journal-title":"Crit. Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e110183","DOI":"10.1371\/JOURNAL.PONE.0110183","article-title":"The \u201cgenomic storm\u201d induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation","volume":"9","author":"DiGiandomenico","year":"2014","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/BLOOD-2012-06-437392","article-title":"Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice","volume":"121","author":"Duerschmied","year":"2013","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/J.DRUDIS.2012.02.009","article-title":"Impact of 5-HT\u2083 receptor antagonists on peripheral and central diseases","volume":"17","author":"Fakhfouri","year":"2012","journal-title":"Drug Discov. Today"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/S12967-022-03401-Y","article-title":"Association between early ondansetron administration and in-hospital mortality in critically ill patients: Analysis of the MIMIC-IV database","volume":"20","author":"Fang","year":"2022","journal-title":"J. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/J.CNC.2017.10.010","article-title":"Gastrointestinal motility problems in critically ill patients","volume":"30","author":"Frazer","year":"2018","journal-title":"Crit. Care Nurs. Clin. North Am."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/J.1365-2036.2004.02180.X","article-title":"Review article: Serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility","volume":"20","author":"Gershon","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/HEP.30361","article-title":"Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice","volume":"69","author":"Gong","year":"2019","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e17354","DOI":"10.1097\/MD.0000000000017354","article-title":"Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): Study protocol for a randomized controlled trial","volume":"98","author":"Guan","year":"2019","journal-title":"Medicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3389\/FIMMU.2018.01511","article-title":"Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome","volume":"9","author":"Hawkins","year":"2018","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/S10147-015-0823-6","article-title":"Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: A prospective randomized crossover study","volume":"20","author":"Kitayama","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/J.CLNESP.2018.04.003","article-title":"Cost analysis of Omega-3 supplementation in critically ill patients with sepsis","volume":"25","author":"Kyeremanteng","year":"2018","journal-title":"Clin. Nutr. ESPEN"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/J.CHEST.2016.11.036","article-title":"Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study","volume":"151","author":"Marik","year":"2017","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/J.EJPHAR.2009.03.041","article-title":"Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats","volume":"614","author":"Nishiyama","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/J.GASTRO.2007.05.019","article-title":"Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis","volume":"133","author":"Nocito","year":"2007","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/CCM.0000000000003342","article-title":"Epidemiology and costs of sepsis in the United States-an analysis based on timing of diagnosis and severity level","volume":"46","author":"Paoli","year":"2018","journal-title":"Crit. Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/S12879-017-2396-7","article-title":"Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: A meta-analysis","volume":"17","author":"Pontrelli","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/J.1365-2036.1993.TB00087.X","article-title":"Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome","volume":"7","author":"Prior","year":"1993","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMP1707170","article-title":"Recognizing sepsis as a global health priority - a WHO resolution","volume":"377","author":"Reinhart","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/ANNONC\/MDS541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2013","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/03009740410007050","article-title":"Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone","volume":"119","author":"Samborski","year":"2004","journal-title":"Scand. J. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/J.INTIMP.2011.08.022","article-title":"Experimental examination of anti-inflammatory effects of a 5-HT3 receptor antagonist, tropisetron, and concomitant effects on autonomic nervous function in a rat sepsis model","volume":"11","author":"Setoguchi","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/APHA.12430","article-title":"The role of serotonin and its receptors in activation of immune responses and inflammation","volume":"213","author":"Shajib","year":"2015","journal-title":"Acta Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/JAMA.2016.0287","article-title":"The third international Consensus Definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/17425255.2017.1396317","article-title":"Granisetron: A review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting","volume":"13","author":"Spartinou","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/J.JCRC.2021.07.015","article-title":"Effects of ondansetron use on outcomes of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database","volume":"66","author":"Tao","year":"2021","journal-title":"J. Crit. Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/S00520-011-1185-X","article-title":"Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: A double-blind, randomized, non-inferiority trial","volume":"20","author":"Tsuji","year":"2012","journal-title":"Support. Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/09629350400014123","article-title":"Influence of serotonin on the analgesic effect of granisetron on temporomandibular joint arthritis","volume":"13","author":"Voog","year":"2004","journal-title":"Mediat. Inflamm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/J.BBRC.2018.12.031","article-title":"Granisetron protects polymicrobial sepsis-induced acute lung injury in mice","volume":"508","author":"Wang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1097\/CCM.0000000000004155","article-title":"The epidemiology of sepsis in Chinese ICUs: A national cross-sectional survey","volume":"48","author":"Xie","year":"2020","journal-title":"Crit. Care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1995-7645(13)60082-6","article-title":"Risk factors of gastroparesis syndrome after abdominal non-gastroduodenal operation and its prevention","volume":"6","author":"Yang","year":"2013","journal-title":"Asian pac. J. Trop. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6374283","DOI":"10.1155\/2017\/6374283","article-title":"5-HT drives mortality in sepsis induced by cecal ligation and puncture in mice","volume":"2017","author":"Zhang","year":"2017","journal-title":"Mediat. Inflamm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1013284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:14:06Z","timestamp":1670908446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1013284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.1013284"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1013284","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"1013284"}}